Evidence map›Paper›PMID 24692193›Full record

ReviewCold Spring Harbor perspectives in medicine2014

Fungal diagnostics.

Thomas R Kozel, Brian Wickes

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025
    Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas R KozelDepartment of Microbiology and Immunology, University of Nevada School of Medicine, Reno, Nevada 89557.
Brian Wickes

Funding

Cryptococcal polysaccharide-phagocytosis inhibitionR01AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1985 to 2009
$1.9M
Lateral Flow Assay for Diagnosis of HistoplasmosisR44AI096945 · NIAID · IMMUNO-MYCOLOGICS, INC. · PI BAUMAN, SEAN · 2015 to 2016
$1.8M
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITIONR37AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1995 to 2004
$1.5M
Target discovery and immunoassay for diagnosis of invasive aspergillosisR33AI085548 · NIAID · UNIVERSITY OF NEVADA RENO · PI AUCOIN, DAVID P, KOZEL, THOMAS R · 2012 to 2014
$1.1M
Immunoassay for diagnosis of invasive fungal diseaseR41AI102311 · NIAID · IMMUNO-MYCOLOGICS, INC. · PI CRIDER, BEVERLY, KOZEL, THOMAS R · 2013 to 2014
$600k
Biomarker discovery for immunodiagnosis of invasive candidiasisR41AI108114 · NIAID · DXDISCOVERY, INC. · PI KOZEL, THOMAS R · 2013 to 2014
$600k
Point-of-care immunoassay for diagnosis of histoplasmosis in HIV/AIDSR41AI096945 · NIAID · IMMUNO-MYCOLOGICS, INC. · PI BAUMAN, SEAN · 2011 to 2012
$589k
Target discovery and immunoassay for diagnosis of invasive aspergillosisR21AI085548 · NIAID · UNIVERSITY OF NEVADA RENO · PI AUCOIN, DAVID P, KOZEL, THOMAS R · 2010 to 2011
$380k
NIAID NIH HHS AI014209NIAID NIH HHS AI085548NIAID NIH HHS AI096945NIAID NIH HHS AI102311NIAID NIH HHS R01 AI014209NIAID NIH HHS R21 AI085548NIAID NIH HHS R33 AI085548NIAID NIH HHS R37 AI014209NIAID NIH HHS R41 AI096945NIAID NIH HHS R41 AI102311NIAID NIH HHS R41 AI108114NIAID NIH HHS R44 AI096945
6 · The paper itself

Abstract

Early diagnosis of fungal infection is critical to effective treatment. There are many impediments to diagnosis such as a diminishing number of clinical mycologists, cost, time to result, and requirements for sensitivity and specificity. In addition, fungal diagnostics must meet the contrasting needs presented by the increasing diversity of fungi found in association with the use of immunosuppressive agents in countries with high levels of medical care and the need for diagnostics in resource-limited countries where large numbers of opportunistic infections occur in patients with AIDS. Traditional approaches to diagnosis include direct microscopic examination of clinical samples, histopathology, culture, and serology. Emerging technologies include molecular diagnostics and antigen detection in clinical samples. Innovative new technologies that use molecular and immunoassay platforms have the potential to meet the needs of both resource-rich and resource-limited clinical environments.

Indexed as

Culture TechniquesDNA FingerprintingFungiHumansMycological Typing TechniquesMycosesOpportunistic InfectionsPolymerase Chain ReactionProteomicsSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Identifiers

PMID24692193
PMCPMC3968782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.